Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

The GLP-1 arena has turned into a boxing match between heavyweights Novo Nordisk and Eli Lilly as the two pharma giants ...

GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Rybelsus, the oral form of Semaglutide launched by Novo Nordisk in January 2022, has grown from Rs 26 crore to Rs 412 crore, ...

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

The two largest health insurers in Massachusetts are effectively telling the drug companies that they may seek a rapidly ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...